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Neurobiology of Disease
FK506-Binding Protein 12.6/1b, a Negative Regulator of
[Ca2], Rescues Memory and Restores Genomic Regulation
in the Hippocampus of Aging Rats
John C. Gant,1* Eric M. Blalock,1* Kuey-Chu Chen,1 Inga Kadish,2 Olivier Thibault,1NadaM. Porter,1
and PhilipW. Landfield1
1Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky 40536, and 2Department of Cell, Developmental and
Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama 35294
Hippocampal overexpression of FK506-binding protein 12.6/1b (FKBP1b), a negative regulator of ryanodine receptor Ca2 release,
reverses aging-induced memory impairment and neuronal Ca2 dysregulation. Here, we tested the hypothesis that FKBP1b also can
protect downstream transcriptional networks from aging-induced dysregulation. We gave hippocampal microinjections of FKBP1b-
expressing viral vector to male rats at either 13 months of age (long-term, LT) or 19 months of age (short-term, ST) and tested memory
performance in the Morris water maze at 21 months of age. Aged rats treated ST or LT with FKBP1b substantially outperformed
age-matched vector controls and performed similarly to each other and young controls (YCs). Transcriptional profiling in the same
animals identified 2342 genes with hippocampal expression that was upregulated/downregulated in aged controls (ACs) compared with
YCs (the aging effect). Of these aging-dependent genes, 876 (37%) also showed altered expression in aged FKBP1b-treated rats compared
with ACs, with FKBP1b restoring expression of essentially all such genes (872/876, 99.5%) in the direction opposite the aging effect and
closer to levels in YCs. This inverse relationship between the aging and FKBP1b effects suggests that the aging effects arise from FKBP1b
deficiency. Functional category analysis revealed that genes downregulatedwith aging and restored by FKBP1bwere associated predom-
inantly with diverse brain structure categories, including cytoskeleton, membrane channels, and extracellular region. Conversely, genes
upregulated with aging but not restored by FKBP1b associated primarily with glial–neuroinflammatory, ribosomal, and lysosomal
categories. Immunohistochemistry confirmed aging-induced rarefaction and FKBP1b-mediated restoration of neuronal microtubular
structure. Therefore, a previously unrecognized genomicnetworkmodulatingdiverse brain structural processes is dysregulatedby aging
and restored by FKBP1b overexpression.
Key words: aging; calcium; cytoskeleton; FKBP12.6; microarray; ryanodine receptor
Introduction
Dysregulation of neuronal Ca2 concentrations and of Ca2-
dependent physiological responses is among the most consistent
neurobiological manifestations of mammalian brain aging (Land-
field and Pitler, 1984; Michaelis et al., 1984; Gibson and Peterson,
1987; Landfield, 1987; Khachaturian, 1989; Reynolds and Carlen,
1989; Thompson et al., 1996; Verkhratsky and Toescu, 1998; He-
mond and Jaffe, 2005;Murchison andGriffith, 2007; Thibault et al.,
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Significance Statement
Previously, we found that hippocampal overexpression of FK506-binding protein 12.6/1b (FKBP1b), a negative regulator of
intracellular Ca2 responses, reverses both aging-related Ca2 dysregulation and cognitive impairment. Here, we testedwhether
hippocampal FKBP1b overexpression also counteracts aging changes in gene transcriptional networks. In addition to reducing
memory deficits in aged rats, FKBP1b selectively counteracted aging-induced expression changes in 37% of aging-dependent
genes, with cytoskeletal and extracellular structure categories highly associated with the FKBP1b-rescued genes. Our results
indicate that, in parallel with cognitive processes, a novel transcriptional network coordinating brain structural organization is
dysregulated with aging and restored by FKBP1b.
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2007; Oh et al., 2010). Further, Ca2 dysregulation has been asso-
ciated with aging-related cognitive dysfunction in multiple spe-
cies (Disterhoft et al., 1996; Thibault and Landfield, 1996;
Tombaugh et al., 2005; Murphy et al., 2006; Luebke and Ama-
trudo, 2012; Gant et al., 2015) and evidence of Ca2 dysregula-
tion also is present in postmortem Alzheimer’s disease (AD)
brains and in mouse models of AD (Nixon et al., 1994; Gibson et
al., 1996; Stutzmann et al., 2006; Kuchibhotla et al., 2008; Overk
and Masliah, 2017).
Little is known about the mechanisms underlying aging-
related Ca2 dysregulation, although a strong candidate mecha-
nism, disruption of FK506-binding protein 12.6/1b (FKBP1b),
has emerged recently. FKBP1b is a member of the FKBP family
of immunophilins (Kang et al., 2008) and in muscle cells is an
established negative regulator of intracellular Ca2 release from
ryanodine receptors (RyRs) (Zalk et al., 2007; Lehnart et al., 2008;
MacMillan and McCarron, 2009).
Recently, we found that FKBP1b negatively regulates Ca2
release from RyRs in brain neurons as well and, additionally,
inhibits Ca2 influx via membrane L-type Ca2 channels (Gant
et al., 2011, 2014, 2015). Selective knock-down of FKBP1b in the
hippocampus of young rats recapitulates the Ca2 dysregulation
aging phenotype of enlarged RyR-dependent Ca2 potentials and
currents (Gant et al., 2011). Further, chronic-stress-induced
FKBP1b disruption is associated with cognitive dysfunction (Liu et
al., 2012). In addition, short term (ST) virally mediated overex-
pression of FKBP1b in rat hippocampus reverses aging-related
elevation of Ca2 transients and spatial memory deficits (Gant et
al., 2015). Moreover, hippocampal FKBP1b protein and gene ex-
pression declines with normal aging in rats (Kadish et al., 2009;
Gant et al., 2015) and in early-stage AD (Blalock et al., 2004).
These findings suggest that FKBP1b is a key regulator of neuronal
Ca2 homeostasis and cognitive processing that is disrupted dur-
ing aging.
Transcriptional and translational processes, notably for the
activity-regulated, cytoskeletal-associated protein (Arc), also have
been linked to memory, synaptic growth, and dendritic remodel-
ing (Steward et al., 1998; Guzowski et al., 2000; Schafe and Le-
Doux, 2000; Ploski et al., 2008; Lee and Silva, 2009; Alberini and
Kandel, 2014; Fletcher et al., 2014), but it is unclear whether they
are modulated by the FKBP1b network. Electrical activity at syn-
apses and plasmalemmal membranes can trigger genomic re-
sponses viamultiple Ca2 signaling cascades or Ca2-dependent
transcription factors (Graef et al., 1999; Gall et al., 2003; Greer
andGreenberg, 2008) and elevated intracellular Ca2 concentra-
tions induce electrophysiological and structural signs of deterio-
ration (Scharfman and Schwartzkroin, 1989; Bezprozvanny and
Mattson, 2008) that activate genomic pathways involved in cell
death. In addition, FKBP1b and its protein isoform, FKBP1a, regu-
latenon-RyR-dependentpathways, including themechanistic target
of rapamycin (mTOR) pathway, which modulates brain-derived
neurotrophic factor (BDNF) and other transcriptionally active fac-
tors (Binder and Scharfman, 2004; Hoeffer et al., 2008; Lynch et al.,
2008). These multiple pathways of potential downstream reg-
ulation make it important to determine whether and how the
Ca2 regulator FKBP1b interacts with plasticity-associated tran-
scriptional processes.
Here, we used amultidisciplinary approach to test the hypoth-
esis that FKBP1b overexpression also counters selective aging-
related alterations in transcription. In addition, to determine
whether long-term (LT) FKBP1b overexpression is safe and effi-
cacious andmay be a candidate preventive therapy, we compared
ST hippocampal FKBP1b overexpression with LT FKBP1b overex-
pression, which is initiated in midlife when memory impairment
first begins to emerge (Forster and Lal, 1992; Gallagher andRapp,
1997; Markowska, 1999; Wyss et al., 2000; Bizon et al., 2009;
Scheinert et al., 2015). Together, the results indicate that LT and ST
virally mediated FKBP1b overexpression can prevent and reverse,
respectively, important aspects of aging-related brain decline.
Materials andMethods
All experiments and procedures were performed in accordance with the
University of Kentucky guidelines and were approved by the Animal
Care and Use Committee. Hippocampal overexpression of FKBP1b was
induced using methods and doses similar to those we described and vali-
dated previously (Gant et al., 2015). Briefly, bilateral injection of adeno-
associated virus (AAV) vector harboring the transgene for FKBP1b under
control of the calmodulin-dependentproteinkinase II (CaMKII) promoter
(AAV2/9.CaMKII 0.4.ratFKBP1b.RGB; or AAV-FKBP1b) into the CA1
region of the hippocampus. A control vector harboring the transgene for
enhanced green fluorescent protein (eGFP) (AAV2/9.CaMKII 0.4.eGF-
P.RGB, or, AAV-eGFP) was administered with the same procedure to a
vector control group of aging rats from the same cohort. The AAV
vectors were constructed at the University of Pennsylvania vector core
(Philadelphia, PA).
A total of 52 male F344 rats completed behavioral training and were
used for this study. The rats were divided into 4 treatment groups:
(1) young controls receiving no injections (YC; n  10, 4–5 months of
age at receipt); (2) LT aged vector control (AC;n 13, bilateral injections
ofAAV-eGFP1.86e13 gene copies (GC)/ml, 2l per side; at 13months of
age; (3) ST FKBP1b (ST) (n  13, bilateral injections of AAV.FKBP1b
1.99e12 GC/ml, 2 l per side, at 19 months of age); and (4) LT FKBP1b
(LT) (n  16, bilateral injections of AAV-FKBP1b 1.99e12 GC/ml, 2 l
per side; at 13 months of age). All aged animals used in this study arrived
together and were housed in our animal care facility for the same duration.
During this period, two AC, two ST animals, and one LT animal could not
complete the study and were euthanized because of poor health.
Infusion was accomplished using a Kopf stereotaxic instrument and
Stoelting QSI microinfusion pump. After anesthesia, small holes were
drilled bilaterally in the subjects’ skulls and the dura was pierced. AAV
constructs were infused via a 10 l Hamilton microsyringe with a 32
gauge needle into the hippocampus at a rate of 0.2 l/min. Stereotaxic
coordinates weremeasured frombregma: 4.5mmcaudal, 3.0mm lateral,
and 1.7–1.9 mm depth from the brain surface based on histological pilot
work.
TheMorris watermaze (MWM)was similar to that used in prior work
(Rowe et al., 2007; Latimer et al., 2014; Gant et al., 2015). Briefly, it
consisted of a 190-cm-diameter black round tub filled with water (26°C).
A 15-cm-diameter escape platform was placed in 1 of 4 pool quadrants 1
cm below the water. The pool was contained within a four-sided black-
curtained enclosure with high-contrast lighted geometric images (90 
90 cm) on three of the curtain walls. Contrast imaging and water maze
acquisition software was used for animal positional tracking and digitiz-
ing (Columbus Instruments) and measures of latency, path length to
platform location, and annulus crossings were recorded.
During the first 4 d (training), the escape platform remained in the
same quadrant and position. Each training day consisted of three trials.
On each trial, the subject was started in a different nongoal quadrant and
the order of the starting quadrant was changed each day. Rats were given
60 s to find the platform and were allowed to stay on the platform for an
additional 30 s. If the platform was not found after 60 s, then the rat was
gently guided to the platform and allowed to stay there for an additional
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30 s. On day 5 (referencememory probe), the platformwas removed and
the subjects were started in the quadrant opposite the goal quadrant and
allowed to swim for 60 s.
On day 8, the platform was placed in a new quadrant location. The
subjects were then given 3 trials, 1 from each nongoal quadrant, to learn
the newplatform location (reversal training). On day 9 (reversalmemory
probe), the platformwas removed and subjects were allowed to swim for
60 s.Onday 10, visual acuity and locomotor abilitywere assessedwith the
platform made visible by raising it 1 cm above the water surface and
hanging a bright white contrasting marker 6 inches above the platform
location. The subjects were again given three trials from each of the three
nongoal quadrants to find the platform.
Three days after the visual acuity task, the brains were harvested for
qRT-PCR, gene chip, and immunohistochemistry studies as in prior
work (Kadish et al., 2009; Searcy et al., 2012; Latimer et al., 2014; Gant et
al., 2015). Animals were anesthetized with pentobarbital (Fatal Plus,
50 mg/kg, i.p.). After perfusion with 150 ml of cold 0.9% saline, the
brains were removed and hemisected. For qPCR and gene chip studies,
the dorsal hippocampus was removed from one hemisphere. This tissue
was placed in RNase-free sample tubes and stored at80°C until further
use. For immunohistochemistry studies, the other hemisphere was post-
fixed overnight in 4% paraformaldehyde, cryoprotected by submersion
in 15% sucrose/PBS solution, and then placed in antifreeze/30% sucrose
solution for storage until sectioning.
Immunohistochemistry (IHC)methods were similar to those we have
described previously (Kadish and Van Groen, 2003; Gant et al., 2015).
Coronal sections (30m) were cut on a freezing sliding microtome. The
following primary antibodies were used for overnight incubation: rabbit
anti-FKBP 12.6 (1:500, sc-98742; Santa Cruz Biotechnology) and mouse
Microtubule Associated Protein-2 (MAP2, 1:500, MAB3418; Millipore).
After incubation, sections were rinsed and transferred to the solution
containing appropriate biotinylated secondary antibody for 2 h and then
rinsed and transferred to the solution containing ExtrAvidin for 2 h.
Sections were then incubated for 3min with Ni-enhancedDAB solution.
To obtain similarly stained material, sections from all animals were
stained simultaneously in the same staining tray. The immunostained
sections of the dorsal hippocampus were digitized using an Olympus
DP73 camera and the resulting images were analyzed using ImageJ. For
optical densitometric analysis ofMAP2 immunohistochemistry, two sec-
tions of the apical dendritic layer (stratum radiatum) of hippocampal
CA1 pyramidal neurons were measured per animal. Investigators were
blinded to animal number and condition and all photomicrographs were
taken with the same settings of the DP73 camera. The staining pattern of
the anti-FKBP 12.6/1b antibody was highly similar to that seen in two
prior studies of hippocampal FKBP1b with this antibody, one in which
we selectively knocked down FKBP1b with short hairpin RNA targeting
FKBP1b (Gant et al., 2011) and one in which we overexpressed FKBP1b
and also compared endogenousFKBP1b in young versusACs (Gant et al.,
2015). In both prior studies, the topography of FKBP1b immunostaining
was highly similar to that in the present study and the antibody clearly
detected the experimental manipulations and the aging difference in
FKBP1b expression in CA1. In addition, the vendor validates antibody
specificity by Western blot analyses and we performed negative control
studies by omitting the primary antibody and using only secondary in
adjacent brain sections from the same subjects. These negative controls
produced no staining in our rat brain tissues.
Dorsal hippocampal RNA was extracted according to standard proto-
cols and evaluated using an Agilent Technologies Bioanalyzer. All
samples were of sufficient quality and did not differ significantly among
treatment groups (RNA integrity number: 9.4  0.1 for all groups; p 
0.16, ANOVAacross the YC,AC, ST, andLT groups). ExtractedRNAwas
used for both PCR andmicroarray measures. For RT-PCRmRNA quan-
tification, one-step real-time qRT-PCR was used. qRT-PCR amplifica-
tion was performed as described previously (Gant et al., 2015) using an
ABI Prism 7700 sequence detection system (Applied Biosystems) and a
RNA-to-CT 1-step TaqMan kit (Life Technologies). All samples were
run in duplicate in a final volume of 30l containing 25–50 ng of cellular
RNA and a Taqman Fam-MGB probe (Rn00575368_m1; Life Technol-
ogies) with an amplicon spanning a 116 bp rat FKBP1b cDNA region.
Cycling parameters for all assays were as follows: 30 min at 48°C, 10 min
at 95°C followed by 40 cycles of 15 s at 95°C, and 1 min at 60°C. The
RNA levels of Gapdh were used as normalization controls for RNA
quantification.
Microarray procedures were similar to those in our prior microarray
studies on hippocampal aging in rats (Blalock et al., 2003; Rowe et al.,
2007; Kadish et al., 2009). Briefly, RNA extracted from dorsal hippocam-
puswas labeled and hybridized toAffymetrix RatGene 1.0 ST arrays (one
array per animal). Gene signal intensities formicroarrays were calculated
using the Robust Multiarray Average algorithm (Bolstad et al., 2003) at
the transcript level and data were associated with vendor-provided an-
notation information.
For experimental design and statistical analyses, see Fig. 1. To test the
hypothesis that expression in selective genomic systems parallels the
changes in memory performance induced by aging and, in the opposite
direction, by FKBP1b rescue, we compared YC rats and AC rats (that
received bilateral injections of AAV-eGFP) with aged rats that received
bilateral dorsal hippocampal injections of AAV-FKBP1b. The FKBP1b-
expressing virus was microinjected into aging rats either 2 months (ST)
or 8 months (LT) before testing spatial reference and reversal learning in
theMWM.All three aged groupswere tested together at 21months of age
along with young (5-month-old) controls (Fig. 1). The reference mem-
ory task tests the ability to learn an aspect of the task that remains con-
stant, whereas reversal learning comprises elements of both working
memory and executive cognitive function (Webster et al., 2014) and is
well recognized to be particularly susceptible to impairment with aging
(Bartus et al., 1979; Stephens et al., 1985). Initial statistical assessments of
behavioral comparisons used ANOVA. If significance was found at
the ANOVA level ( 0.05), then protected Fisher’s least significant
difference (pLSD) pairwise contrasts ( 0.05) between groups were
also performed.
Microarray profiling was undertaken with the goal of identifying the
FKBP1b-sensitive transcriptome. The n’s chosen for microarray studies
were based on our prior work (Blalock et al., 2003; Rowe et al., 2007;
Kadish et al., 2009; Blalock et al., 2010), which found that n’s of 5–10 per
group are sufficient to identify a distinct hippocampal aging transcrip-
tome consistently. For transcriptional profiling in the present study, a
subgroup of six subjects was selected from each of the four parent treat-
ment groups (N  24 rats, one array per rat). To reduce false negatives
and to maximize the transcriptional responses to elevated FKBP1b ex-
pression, we selected subjects for the ST and LT subgroups that showed
FKBP1b expression levels above the medians for the parent groups. The
YC and AC groups exhibited low within-group variance of FKBP1b ex-
Figure 1. Experimental design. To compare LT with ST exposure to FKBP1b overexpression,
aging ratswere bilaterally injected in the hippocampuswith AAV-FKBP1b at twodifferent ages,
one group at 13 months of age (LT) and one group at 19 months of age (ST) (small, vertical
arrows). A third group received control vector (AAV-eGFP) at 13 months of age and a YC group
received no injections. All animals were tested for spatial learning in the MWM, 3 aged groups
at 21months of age and 1 YC group at 6months of age (totalN 52). Animalswere killed after
MWM testing. The mRNA from the dorsal hippocampus of one hemisphere was prepared for
qRT-PCR and microarray analyses and the other hemisphere was postfixed for IHC.
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pression (see Fig. 3) and these subgroups were selected at random from
within their parent groups.
The Rat Gene Array used for the microarray analysis contains 29,218
total probe sets, which we filtered before statistical testing to retain only
the 14,828 probe sets characterized by unique gene annotations and by
signal intensity (expression) adequate to show presence of the gene (de-
fined as unlogged signal intensity 40 on 4 arrays in the study). Ex-
pression of each of these 14,828 genes was tested by one-way ANOVA to
identify genes exhibiting significant differences in expression across the
four groups. Outlier values (2 SDs of the group mean) were treated as
missing values. Transcriptional profiling analyses can involve thousands
of statistical comparisons and thus require assessment ofmultiple testing
error. We estimated the error contributed by multiple testing using the
false discovery rate (FDR) procedure (Benjamini and Hochberg, 1995).
The FDR is the ratio of significant comparisons expected by chance to
significant comparisons actually observed and is an estimate of the probabil-
ity that any single significant gene in a profiling study is a false positive found
due to the error of multiple testing. Therefore, confidence in profiling data
increases as the FDR decreases. Confidence in microarray data is also
strengthened considerably by functional category analyses, which can deter-
mine whether multiple genes in the same functional categories are coregu-
lated (Blalock et al., 2005; Ginsberg andMirnics, 2006).
For functional category analysis in the present study, ANOVA-
significant genes were assigned to one of four expression template pat-
terns defined by post hoc pairwise comparisons between groups (see
Results). Overrepresented functional categories for each expression tem-
plate were determined using Database for Annotation, Visualization and
Integrated Discovery (DAVID) bioinformatic tools (Huang da et al.,
2009) with the list of 14,828 filtered genes as a background. Raw data are
available through the Gene Expression Omnibus (GSE #: 102054).
To determine the functional categories/pathways that were closely as-
sociated with each of the four template patterns, functional pathway
analysis was performed as in prior work (Blalock et al., 2003, 2004; Rowe
et al., 2007; Kadish et al., 2009; Chen et al., 2013). Genes assigned to each
of the four template patterns were tested statistically ( 0.05) using a
modified Fisher’s exact test p-value referred to as the “Ease Score” in the
DAVID suite of bioinformatic tools (Huang da et al., 2007). This ap-
proach was used to test the Gene Ontology (GO) database (biological
process, cellular component,molecular function) for categories overrep-
resented by genes of each template pattern. Medium classification strin-
gency was applied. Functional annotation clustering output from
DAVID was transferred to flat files and the most significant annotation
fromwithin each cluster was identified. Among these, unique functional
annotations with significant Ease Scores are reported along with the
number of associated pathway genes.
In a further assessment of possible contributions of chance to these
large-scale analyses, the numbers of genes that were identified as belong-
ing to a particular pattern were compared with the numbers of genes that
would be expected to fall within that pattern by chance. The probability
that a genewould fall into a particular pattern by chancewas estimated by
performing a Monte Carlo analysis in which the same statistical proce-
dures (ANOVA test, post hoc pLSD, and template pattern) and statistical
Figure 2. Both LT and ST FKBP1b overexpression countered age-related decline in spatial
memory. A, Reference memory probe. FKBP1b treatments countered age-related deficits in
reference memory probe performance. B, Reversal memory probe. FKBP1b treatments coun-
tered age-related deficits in the reversal memory probe trial. C, Cued testing. With visual cues
prominently highlighting location of the escape platform, no group differences were found,
indicating that memory test results were not due to differences in locomotor and/or visual
abilities. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001 significant pairwise contrast
versus AC.
Figure 3. Hippocampal FKBP1bmRNA and protein levels were increased substantially by LT
AAV-FKBP1b overexpression. Top, qRT-PCR quantification of hippocampal FKBP1b mRNA ex-
pression (FKBP1b/Gapdh) for each treatment group (one-way ANOVA on ranks, p 0.000050;
for pairwise contrast vs AC; *p0.05; ***p0.001). Bottom, Immunostaining for hippocam-
pal FKBP1b expression. Representative photomicrographs are shown from YC (A), AC (B), aged
ST FKBP1b (C), and aged LT FKBP1b (D). Note the substantial increase in FKBP1b expression at
both themRNAandprotein levels, particularly in the LT-FKBP1bgroup. sp, Stratumpyramidale;
DG, dentate gyrus. Scale bar, 500M.
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criteria (  0.05) were used, but applied to
random numbers rather than actual gene sig-
nal intensity values. The Monte Carlo proce-
dure was rerun 1000 times, with a newly
generated set of random numbers in each iter-
ation. The average number of genes found to
fall within each expression pattern across 1000
iterations of random data was then used as an
estimate of the number of genes expected to fall
within that pattern by chance. The binomial
test ( 0.05) was used to determine whether
the number actually found in the pattern ex-




spatial reference and reversal memory
for both LT and ST aged groups (Fig. 2)
A total of 52 rats in four groups completed
our spatialmemory testing protocol in the
MWM (10 YC, 13 AC, 13 ST, and 16 LT
rats). For the 3 groups of aged AAV-
treated rats, behavioral testing began at 21
months of age, either 8 (LT) or 2 (ST)
months after AAV injection. Training in
the MWM reference memory task was
performed over 4 d, with 3 training trials
per day. Over the 4 d, all groups showed
acquisition of the task as indicated by a
distinct decline in latency and path-length
to find the platform (F(11,528) 11.58 p
1.80e-10; F(11,528)  7.41, p  7.20e-12,
respectively, repeated-measures ANOVA).
Although there was a strong trend for
young animals to outperform ACs during
training, no significant effects of treat-
ment were seen in latency and path length measures over this 4 d
training phase, similar to results in Gant et al. (2015).
On the fifth day of the task, the platform was removed and
recall of the platform location was probed with a single retention
trial (Fig. 2A; reference memory probe). There was a main effect
of treatment group for both latency (F(3,48)  3.57, p  0.021,
ANOVA) and path length (F(3,48) 2.90, p 0.044, ANOVA). As
reported in multiple studies, the AC group exhibited significantly
longer path lengths and higher latencies to find the platform
comparedwith YC rats. In contrast, neither FKBP1b-treated aged
group differed from YCs and both showed significantly reduced
latency compared with ACs (vs ACs: LT, p 0.05, ST, p 0.05;
YCs, p 0.002, pLSD). The path length to platform results were
highly similar to latency, although the differences between the
FKBP1b groups and the ACs were only of borderline significance
(vs ACs: LT, p 0.078; ST, p 0.08, YCs, p 0.006, pLSD).
Training on the reversal memory task was conducted on the
eighth day after 2 d of rest: The location of the platform was
changed and the rats were given 3 trials in 1 d to learn the new
location. Over the three reversal training trials, there were no
significant differences in latency or path length among any of the
groups, norwas there significant improvement (data not shown).
On the ninth day, the platform was again removed and rats were
tested for their retention of the new platform location on a single
retention trial (Fig. 2B, reversal memory probe). There were
substantial main effects of treatment on latency to platform
(F(3,48) 9.57, p 0.000046, ANOVA) and path length to plat-
form location (F(3,48) 7.97, p 0.0002, ANOVA). AC animals
again exhibited highly significant deficits in path length and la-
tency compared with YCs, but both ST and LT groups exhibited
path length and latency scores that were highly similar to those of
YCs and significantly reduced compared with AC animals (la-
tency; AC vs: LT, p  0.0001, ST, p  0.0001; YC, p  0.0001;
path length, AC vs: LT, p  0.0001, ST, p  0.0001; YC, p 
0.0008, pLSD; Fig. 2B). There was also a main effect of treatment
group for platform crossings during the reversal retention test
(F(3,48)  7.37, p  0.0004; ANOVA), with the YC, ST, and LT
groups showing significantly greater platform crossings com-
pared with ACs (ACs vs: YCs, p 0.0001; ST; p 0.025; LT, p
0.01, pLSD).
On the 10 th day of the protocol, a cued retention test was given
with visual cues highlighting the platform’s location. All groups
found the platform rapidly and no significant group differences
were present in latency, path length, or swim speed in locating the
platform (Fig. 2C, cued trial), indicating that aging-related changes
in locomotor and visual acuity did not account for the differences in
memory performance.
The ST and LT groups were statistically indistinguishable
from each other on all latency and path length measures in the
behavioral testing protocols. These results suggest that the
reversal by ST and prevention by LT of aging-dependent mem-
ory impairment may be mediated by similar cellular mecha-
nisms despite the differences in the duration of exposure.
Figure 4. Microarray analysis flowchart. Shown are the effects of aging and FKBP1b on hippocampal gene transcription. Left,
Total gene probe sets (29,218) were filtered to remove absent (low signal intensity) and incompletely annotated probe sets. The
remaining genes (14,828)were tested by ANOVA ( p 0.05) followed by pairwise comparison (Fisher’s pLSD, 0.05 between YC
and AC) to define aging-dependent genes. Right, Statistical template algorithm. Aging-dependent geneswere categorized based
onwhether FKBP1b had no effect (templates I and III) or significantly countered aging’s effect (templates II and IV). A total
of 99.8% of aging-dependent genes were assigned to a template based on criteria described in the text. A Monte Carlo
simulation (1000 iterations, see Results) was used to estimate the number of genes expected in each template by chance.
The number of genes assigned to each template in the observed data was significantly greater than the number expected
by chance ( p  0.0001; binomial test; 11-fold increase for all templates). See also Figure 4-1 (available at
https://doi.org/10.1523/JNEUROSCI.2234-17.2017.f4-1).
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AAV-FKBP1b injection increased hippocampal FKBP1b
protein and gene expression, particularly in the LT group
(Fig. 3)
Because the Affymetrix Rat Gene 1.0 ST microarray used in the
present study does not include the probe set for FKBP1b, we used
qRT-PCR to evaluate the effectiveness of AAV-FKBP1b injection
for inducing FKBP1b expression in hippocampus. FKBP1b/
Gapdh expression is plotted as a function of treatment group in
Figure 3. Therewas a highly significant increase inFKBP1b expression
(F(3,47)18.449, p 0.000050, ANOVAon ranks, Kruskal–Wallis).
By pairwise contrast (Fisher’s LSD on ranks), the increased expres-
sion was significant in ST (p 0.012) and highly significant in LT
(p  0.001). IHC in representative animals indicated that hip-
pocampal FKBP1b protein upregulation paralleled FKBP1bmRNA
increases in AAV-FKBP1b-treated rats and was particularly intense
in LT animals (Fig. 3, bottom).
In contrast to our prior findings (Blalock et al., 2004; Kadish et
al., 2009; Gant et al., 2015), we did not observe differences in
endogenous FKBP1b expression between the AC and YC groups
(Fig. 3, top). This may be due to differences between studies in
tissue dissection. In the present study, we collected tissue from
whole dorsal hippocampus, whereas in prior work, we measured
expression primarily in the CA1 region (Blalock et al., 2004;
Kadish et al., 2009; Gant et al., 2015). Therefore, the aging effect
on FKBP1b in CA1might have been obscured in the present work
because of dilution from less age-sensitive hippocampal regions.
Further studies will be needed to fully elucidate the topographic
distribution of aging changes inFKBP1bprotein and gene expres-
sion, aswell as the role of potential functional changes (Lehnart et
al., 2008).
Transcriptional profiling (Fig. 4)
To identify genes with expression that paralleled aging and
FKBP1b’s cognitive effects in the same animals, we first distin-
guished genes that changed expression with aging (i.e., differed
between ACs and YCs, the aging effect). We then identified those
genes among the aging-dependent genes that were also altered by
FKBP1b overexpression (i.e., differed between LT/ST FKBP1b
and AC, the FKBP1b effect). RNA from six subjects per treatment
group was prepared and hybridized to Affymetrix Rat Gene 1.0
arrays. Of the 	30,000 probe sets on the array, we filtered to
retain 14,828 annotated, present genes (see Materials and Meth-
ods) for statistical analysis. One-way ANOVA (p 0.05) showed
that 24% (3502) differed significantly across the four groups,
yielding an FDR of 0.12 (see Materials andMethods). An FDR of
0.12 is quite low for a microarray study of brain aging and pro-
vides considerable confidence in these results. Reliability in mi-
croarray studies is also strengthened when functional categories
are overrepresented by coregulated genes (Blalock et al., 2005;
Galvin and Ginsberg, 2005; Ginsberg and Mirnics, 2006).
Among ANOVA-significant genes (3502), 2342 (67%) also dif-
fered significantly in pairwise contrast (Fisher’s protected LSD; p
0.05) between the YC and AC groups (aging-dependent genes,
“the aging effect”). Among these, the expression levels of 37%
(876/2342) genes were also altered by FKBP1b overexpression
(517 by LT, 193 by ST, 166 by both ST and LT, “the FKBP1b
effect”) and were defined as aging and FKBP1b-sensitive genes
(for a complete list of aging- and FKBP1b-sensitive genes, see Fig.
4-1, available at https://doi.org/10.1523/JNEUROSCI.2234-17.
2017.f4-1). Many more of these were altered by both ST and LT
(166) than would be expected by chance if ST and LT treatments
acted through independent mechanisms (p  4.8E-9, binomial
test). These results suggest that LT and ST FKBP1b treatments
exerted similar transcriptional effects. To determine whether this
agreement between ST and LT was limited primarily to the 166
genes in the overlap or instead reflected widespread similarity
among most FKBP1b-sensitive genes, we tested the correlation
Table 1. Functional categories overrepresented by genes assigned to the four expression templates reflecting aging FKBP1b sensitivity
I. Downregulated with age, unchanged by FKBP1b n p-value II. Downregulated with age, upregulated by FKBP1b n p-value
Serine hydrolase activity 18 0.0019 Cytoskeleton 39 9.6E-04
Cellular amino acid derivative biosynthesis 9 0.0029 Passive transmembrane transporter activity 19 0.0039
Integral to plasma membrane 27 0.0050 Extracellular region 41 0.0080
Amine metabolic process 27 0.0082 Ectoderm development 8 0.0249
Tissue morphogenesis 19 0.0150 Regulation of actin cytoskeleton 6 0.0265
Positive regulation of gene expression 36 0.0341 Metalloendopeptidase activity 6 0.0335
Regulation of MAP kinase activity 8 0.0387
III. Upregulated with age, unchanged by FKBP1b n p-value IV. Upregulated with age, downregulated by FKBP1b n p-value
Translational elongation 36 5.9E-23 Extracellular matrix 20 1.0E-04
Lysosome 35 2.7E-13 Primary transmemb. Transporter activity 11 9.1E-04
Immune system process 76 5.0E-11 Regulation of cell motion 15 0.0010
Endosomal part 12 3.4E-06 Basolateral plasma membrane 15 0.0021
Immune effector process 21 3.7E-06 Golgi cisterna 6 0.0027
Ribosomal small subunit biogenesis 7 2.0E-05 Blood vessel development 16 0.0035
Leukocyte activity during immune response 11 2.3E-05 Membrane-bounded vesicle 29 0.0076
Antigen processing and presentation 15 4.0E-05 Response to oxygen levels 13 0.0162
Response to stress 97 7.3E-05 Response to estrogen stimulus 10 0.0246
T cell activation 15 0.0010 Membrane organization 16 0.0247
Regulation of acute inflammatory response 8 0.0020 Intracellular transport 23 0.0281
Protein kinase cascade 26 0.0036 Organelle membrane 39 0.0385
Carbohydrate binding 25 0.0045 Homeostasis of number of cells 8 0.0419
Protein amino acid phosphorylation 44 0.0056
Response to oxidative stress 18 0.0095
Response to lipid 7 0.0134
Cell-cell adhesion 17 0.0324
Shown are gene ontology category annotations overrepresented by genes exhibiting expression patternsmatching one of the four templates (Fig. 4) in direction of change and sensitivity to FKBP1b listed in order of significance. Left: Aging
effect unchanged by FKBP1b. Right: Aging effect countered (opposite direction change) by FKBP1b. (n, number significant genes in category; p-value, modified Fisher’s exact test/EASE score). Also see Table 1-1 (available at
https://doi.org/10.1523/JNEUROSCI.2234-17.2017.t1-1).
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between LT and ST effects across all 876 FKBP1b-sensitive genes.
A highly significant proportion of FKBP1b-sensitive genes (822/
876; 93.8%) were changed in the same direction by both ST and
LT (p 1E-12, binomial test). Further, the effect sizes of ST and
LT treatment genes (expressed as log2-fold change vs AC) were
strongly correlated (r 0.85, p 1.3E-24; Pearson’s test, data not
shown). These results indicate that ST and LT FKBP1b treatments
influenced gene expression similarly. The ST and LT groups also
performed nearly identically on all behavioral measures. Based on
these similarities and because the genome ontology functional cate-
gory analysis (see below) provides greater statistical confidence in
overrepresentation of a given category with increasing numbers of
genes assigned to that functional category, we combined the ST and
LT lists of FKBP1b-sensitive genes into a single list, such that a gene
was considered an FKBP1b-sensitive gene if it differed from ACs
with ST and/or LT treatment.
Remarkably, only four of the 876 aging-dependent andFKBP1b-
sensitive genes (Eif3g, Pla2g7, S100, and Snapc2) exhibited exac-
erbation of aging effects by FKBP1b, whereas the other 872 changed
in opposite directions with aging and FKBP1b treatment. Accord-
ingly, the anomalous four genes were excluded from functional cat-
egory analyses and the remaining aging-dependent genes (2338)
were parsed into one of four gene expression templates (Fig. 4, right,
templates I–IV), which reflected direction of a gene’s expression
change with aging (up or down) and whether the gene did (Fig. 4,
templates II and IV), or did not (Fig. 4, templates I and III) show the
counteracting effect ofFKBP1b treatment (LTorSTvsAC;p0.05,
Fisher’s post hoc LSD).
To determine whether the number of genes identified in each
template was greater than expected by chance, we ran a Monte
Carlo simulation using the same statistical analysis and template
assignment strategy, but with randomly generated numbers sub-
stituted for signal intensity values (see Materials and Methods).
The numbers of genes actually observed for each reported pattern
exceeded by11-fold the number expected by chance based on
the simulation (Fig. 4; 0.00001, binomial test for each pattern),
indicating a strong biological effect.
GO functional categories associated with genes matching each
of the four template patterns (Fig. 4) of aging- and
FKBP1b-sensitive genes (Table 1)
Lists of genes assigned to each of the four expression templates de-
scribed above (Fig. 4) were uploaded separately to DAVID (Huang
da et al., 2007) and the biological process, cellular component, and
molecular function gene ontologies were interrogated. In each sig-
nificant cluster, the most statistically overrepresented functional
category by DAVID analysis with more than three genes was
retained. The retained functional categories for each of the four
templates are shown in Table 1 (for individual genes associated
with each identified functional pathway, see Table 1-1, available
at https://doi.org/10.1523/JNEUROSCI.2234-17.2017.t1-1).
Genes downregulated with aging and unchanged by FKBP1b
(AC downregulated vs YC, template I) overrepresented GO an-
notations associated with neurotransmitter metabolism and bio-
synthesis in neurons. Their downregulation with aging may
reflect a reduction of neuronal growth and synthetic processes.
Genes upregulatedwith aging and unchanged by FKBP1b (AC
upregulated vs YC, template III) very strongly overrepresented
functional categories associated with upregulated translational
elongation, lysosome activity, and immune signaling, which ap-
pear to reflect major turnover of proteins, cholesterol transport,
and new biosynthesis of apolipoproteins by astrocytes, as well as
activated neuroinflammatory signaling bymicroglia. Similar pat-
terns have been seen in multiple studies (Weindruch and Prolla,
2002; Blalock et al., 2003; Rowe et al., 2007; Kadish et al., 2009;
VanGuilder et al., 2011; Chen et al., 2013). Surprisingly, inflam-
matory responses have generally not been found to correlate
closely with learning or memory (Rowe et al., 2007; Kadish et al.,
2009; VanGuilder et al., 2011) and their resistance to counterac-
tion by FKBP1b, seen here, extends those prior findings.
Genes downregulated with aging and upregulated by FKBP1b
(AC downregulated vs YC, FKBP1b upregulated vs AC, template II)
strongly overrepresented GO categories related to intracellular and
extracellular structure, including: cytoskeleton, extracellular region
passive transmembrane transporter activity, ectoderm devel-
opment, regulation of actin cytoskeleton organization, and
regulation of MAP kinase activity (Table 1), as considered
further in Discussion.
Genes upregulated with aging and downregulated by FKBP1b
(AC upregulated vs YC, FKBP1b downregulated vs AC, template
IV) overrepresentedGO category annotations related to extracel-
lular remodeling and transporter activity, including extracellular
matrix, primary transmembrane transporter activity, blood vessel
development, regulation of cell motion, and membrane-bounded
vesicle (Table 1), potentially reflecting extracellular reorganization,
glial and endothelial cell cytokinesis, and transport of substances
between activated cells.
MAP2: downregulation with aging and restoration by
FKBP1b (Fig. 5, Table 2)
The “cytoskeleton” category was the most statistically significant
downregulated with aging and upregulated by FKBP1b func-
tional category and has been consistently identified as being age
dependent in our prior studies on hippocampal gene expression
associations with memory (Blalock et al., 2003; Rowe et al., 2007;
Kadish et al., 2009). Accordingly, to confirm that these gene ex-
pression alterations were reflected in cytoskeletal changes at the
protein level, we used semiquantitative IHC to analyzeMAP2, an
abundant somatodendriticMAP that reflects general microtubu-
lar structure (Fig. 5). MAP2 protein expression was significantly
reduced (F(3,18)  7.792, p  0.0015, ANOVA, **post hoc pLSD
p 0.001)with age and rescued by LT treatment (pLSD p 0.01)
and possibly ST treatments (borderline significant, pLSD p 
0.06), consistent with the view that the cytoskeletal genomic al-
terations are reflected in overall function and protein structure of
the cytoskeleton.
Possible downstreammediators of FKBP1b effects
Calpain-1, calcineurin, and other Ca2-related genes (Table 3)
Because FKBP1b is a negative regulator of hippocampal neuronal
Ca2 transients (Gant et al., 2011, 2015), it seemed feasible that
pathological Ca2-related signaling during aging might be re-
stored to young levels by FKBP1b overexpression. We therefore
identified all Ca2-related genes on the microarray and deter-
mined which showed age-related changes in gene expression that
were significantly countered by FKBP1b treatment (i.e., met the
criteria for template II or IV in Fig. 4). Although Ca2-related
genes as a category did not show significant overrepresentation of
geneswith aging changes thatwere countered by FKBP1b, the genes
for two Ca2-sensitive enzymes frequently associated with brain
aging, neuronal plasticity, and AD, Cpn-1 (calpain-1) and
Ppp3cc (calcineurin, Nixon et al., 1994; Rozkalne et al., 2011;
Furman and Norris, 2014), as well as a Ca2 release-activated
Ca2 channel (ORAI1) were altered by aging and restored by
FKBP1b treatment (Table 3). Therefore, these Ca2-related genes
may be sensitive downstream mediators of some aspects of both
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age-dependent neuronal Ca2 dyshomeostasis and restoration of
regulation by overexpression of FKBP1b.
mTOR pathway genes
Genes in themTORpathwaywere also of specific interest because
this pathway is inhibited by the immunosuppressant drug rapamy-
cin via complex formation with FKBP1b/1a. Moreover, FKBP1a, a
close isoform of FKBP1b, negatively regulates mTOR in the brain,
even in the absence of rapamycin (Hoeffer et al., 2008). These
interactions of FKBPs andmTOR appear to occur independently
of FKBP1b/1a-dependent regulation of Ca2 release from RyRs.
Therefore, to determine whether mTOR pathway expression is
altered by FKBP1b activity, we investigated mTOR pathway gene
expression relative to FKBP1b overexpression. Twenty-four
mTOR pathway genes were identified by searching the GO data-
base and the literature (Johnson et al., 2013). Of these 24, only
two, Hif1an and Nfkb1, were significantly altered with both age
(upregulated) and FKBP1b (downregulated), showing that the
mTORpathwaywas not statistically overrepresented by FKBP1b-
sensitive genes (n.s., p  0.78, binomial test). Protein–protein
interactions importantly regulate mTOR signaling. Nevertheless,
the lack of change in mTOR pathway gene expression suggests
that FKBP1b’s genomic effects were not mediated by the mTOR
pathway.
Discussion
The present studies provide the first evidence that FKBP1b, a
negative regulator of intracellular [Ca2], modulates a previously
unrecognized genomic network regulating structural organiza-
tion of the brain. In the hippocampus, this network appears to be
specifically targeted and dysregulated by aging. However, as
shown here, FKBP1b overexpression can largely reverse or pre-
vent aging-dependent alterations in gene expression in the net-
work. In this study, FKBP1b overexpression restored regulation
of this network in parallel with cognitive rescue in the same aged
rats. Therefore, this genomic evidence adds strong new support
for the hypothesis that FKBP1b is a linchpin of neuronal homeo-
stasis that functions at multiple levels, including regulation of
Ca2, maintenance of structural integrity, and preservation of
cognitive function.
Aging-induced changes in gene expression
As in our priorwork, we found a high proportion of hippocampal
genes (2342/14,928) that were altered significantly with aging
(Fig. 4, the “aging effect”). Further, the expression levels of 37%
of these aging-altered genes also differed significantly between
AC and aged FKBP1b rats (876/2342 genes, the “FKBP1b effect”).
Regardless of whether the aging effect for a given gene was up-
regulation or downregulation, FKBP1b shifted the expression
levels for essentially all of these genes (872 of 876, 99.5%) back
toward their YC levels. This remarkably consistent restorative
action of FKBP1b strongly suggests that disruption of FKBP1b or
closely associatedmoleculesmay underlie a significant portion of
the aging effect for the 872 FKBP1b-regulated genes.
Nevertheless, deficient FKBP1b function does not account for
all aspects of genomic change with brain aging. Of the aging-
altered genes, amajority (1462/2342,	63%)were not affected by
FKBP1b overexpression. Notably, those associated with upregu-
lated glial-inflammatory processes were unaffected by FKPB1b
(Table 1). Therefore, it appears that other aging processes (e.g.,
glial) also modulate hippocampal transcription, but operate in-
dependently from or upstream of the FKBP1b-sensitive genomic
network.
FKBP1b overexpression reveals an apparent genomic network
that regulates neuronal structure and is targeted by aging
FKBP1b-restored genes were predominantly associated with GO
functional categories related to diverse components of brain struc-
ture. In particular, “cytoskeleton,” “passive membrane transport”
(ion channel proteins that add structure to lipid bilayer mem-
branes), and “extracellular region”were the three functional catego-
ries most overrepresented by genes with expression that declined
with aging and increased with FKBP1b (Table 1). The “cytoskel-
eton “category was represented by numerous genes related to
actin, intermediate filaments, and microtubule assembly, whereas
the extracellular region category was represented by multiple genes
encoding collagens and matrix metalloproteinases, two families
essential for extracellularmatrix assembly/remodeling. Similarly,
among genes with expression that increased with aging and de-
clined with FKBP1b, the most overrepresented category was “ex-
tracellular matrix,” which, despite also focusing on extracellular
space, was represented by a markedly different group of genes.
The “extracellular matrix” category included genes encoding
proteoglycans, growth factors, and other proteins associatedwith
glial activation and blood vessel development (Table 1 and Table
1-1, available at https://doi.org/10.1523/JNEUROSCI.2234-17.
2017.t1-1). These patterns of expression in FKBP1b-sensitive ag-
ing genes appear to reflect an aging-related shift in biosynthetic
Figure 5. FKBP1b counters the age-related decrease in hippocampal MAP2 protein expres-
sion. Top, Semiquantitative measures of MAP2 IHC staining densities plotted as a function of
treatment. Statistical analysis revealed a significant effect ( p 0.0015; one-way ANOVA)with
a significant decrease from YC to AC that was countered by ST FKPB1b (**p 0.01, ***p
0.001, †n.s. trend p 0.06; post hoc Fisher’s pLSD vs AC). Bottom, Immunostaining for hip-
pocampal MAP2 expression. Representative photomicrographs are shown from YC (rectangle
defines region of quantitation; A), AC (B), aged ST FKBP1b (C), and aged LT FKBP1b (D). Scale
bar, 500M.
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activity and differentiation from neuronal and extracellular
structure to glial processes/compartments. The disparate struc-
tural systems altered by aging and restored by FKBP1b suggest the
operation of a novel genomic network that coordinates structural
assembly among diverse brain components. This network is par-
ticularly targeted by aging, but the disruptive effects of aging can,
as shown here, be prevented or reversed by FKBP1b overexpres-
sion in neurons.
Table 2. FKBP1b counters age-related downregulation of cytoskeletal gene expression
Gene Description
Controls
Short- term Long-term ANOVA p-valueYoung Aged
Actr1a ARP1 actin-related prot0.1 homolog A 843 10 753 18 811 15 801 15 0.0046
Add1 adducin 1 (alpha) 2156 15 2051 38 2155 20 2061 24 0.0096
Arl8b ADP-ribosylation factor-like 8B 3935 28 3603 86 3778 43 3817 40 0.0037
Calm2 calmodulin 2 8691 58 8281 104 8606 33 8449 69 0.0037
Ccdc99 coiled-coil domain containing 99 91 2 77 1 90 3 81 2 0.0007
Cort cortistatin 296 2 272 8 274 5 294 5 0.0068
Csrp3 cysteine and glycine-rich protein 3 54 1 43 2 47 2 51 2 0.001
Csta cystatin A (stefin A) 105 4 84 2 95 4 104 7 0.0181
Dnai2 dynein, axonemal, intermediate chain 2 80 2 70 4 73 2 81 3 0.0311
Emd emerin 752 5 707 10 739 9 708 8 0.0015
Gphn gephyrin 839 10 774 28 847 8 810 14 0.0296
Kb23 type II keratin Kb23 301 8 175 10 228 28 253 23 0.0027
Kifap3 kinesin-associated protein 3 2442 26 2264 23 2373 24 2366 20 0.0007
Krt10 keratin 10 73 3 59 2 61 2 73 5 0.0127
Krt17 keratin 17 65 2 53 2 62 2 67 2 0.0012
Krt23 keratin 23 (histone deacetylase inducible) 59 2 52 1 55 2 61 2 0.0117
Krt24 keratin 24 55 1 47 1 51 1 51 1 0.0014
Krt28 keratin 28 99 3 87 3 86 2 101 4 0.0037
Krt33b keratin 33B 166 9 122 4 137 8 164 11 0.0064
Krt9 keratin 9 153 3 121 4 123 4 149 4 6.0E-06
Krtap1–5 keratin associated protein 1–5 66 3 55 3 58 0 64 1 0.0174
Lmnb2 lamin B2 121 1 111 3 118 2 123 3 0.0238
Mk1 Mk1 protein 61 2 51 2 59 1 54 3 0.0176
Myoz3 myozenin 3 359 2 336 8 359 6 357 6 0.0478
Pfn2 profilin 2 3277 33 2970 63 3134 33 3138 24 0.0006
Pja2 praja ring finger 2 4192 50 3998 53 4203 26 4060 13 0.0037
Ppp2ca protein phosphatase 2 alpha 4039 35 3762 46 3946 15 3929 24 0.0001
Ppp4c protein phosphatase 4, catalytic subunit 739 13 648 32 689 12 742 11 0.0063
Prph peripherin 96 3 82 2 87 2 95 5 0.0309
Sec62 SEC62 homolog (S. cerevisiae) 1106 9 1044 6 1095 19 1085 14 0.031
Sept4 septin 4 2445 66 2035 145 2392 77 2371 68 0.0313
Sept7 septin 7 2249 25 2123 40 2288 28 2279 36 0.0115
Shroom4 shroom family member 4 141 2 115 5 126 5 136 6 0.0138
Tmem200a transmembrane protein 200A 2344 36 2001 46 2072 50 2303 29 2.0E-05
Tns4 tensin 4 64 1 56 2 60 1 66 2 0.0008
Trim32 tripartite motif-containing 32 1640 15 1482 23 1494 36 1608 28 0.0009
Trip10 thyroid hormone receptor interactor 10 252 6 224 7 241 8 261 8 0.0158
Tuba1c tubulin, alpha 1C 2354 28 2131 27 2150 43 2309 33 0.0003
Ywhaz tyrosine 3/5-monooxygenase zeta 5666 36 5491 47 5655 38 5506 37 0.0074
Gene symbols, descriptions,meanexpression level (SEM)per group, andone-wayANOVAp-values are reported. Genes shownare the39 cytoskeletal categorygenes identified in Table 1 (template II) thatweredownregulated significantly
with aging and upregulated by FKBP1b treatment.






Downregulated with age, upregulated by FKBP1b
Cab39 Calcium binding protein 39 1499 15 1387 30 1483 16 1469 19 0.0074
Cabp4 Calcium binding protein 4 193 02 162 07 170 07 181 04 0.0034
Calm2 Calmodulin 2 8691 58 8281 104 8606 33 8449 69 0.0037
Calpns1 Calpain, small subunit 1 2910 18 2755 28 2929 24 2838 55 0.0129
Ppp3cb Protein phosphatase 3 (calcineurin), catalytic subunit, beta 3295 36 2942 72 3054 41 3198 53 0.0009
Upregulated with age, downregulated by FKBP1b
Camk1 Calcium/calmodulin-dependent protein kinase I 231 04 262 11 238 06 226 04 0.0089
Capn1 Calpain 1, large subunit 191 04 206 04 198 04 186 02 0.0080
Cib1 Calcium and integrin binding 1 (calmyrin) 145 03 173 03 164 03 156 06 0.0012
Orai1 ORAI calcium release-activated calciummodulator 1 264 04 279 05 263 03 270 03 0.0389
S100a11 S100 calcium binding protein A11 (calgizzarin) 205 11 329 40 221 13 228 15 0.0049
S100a6 S100 calcium binding protein A6 95 02 114 05 103 02 105 01 0.0018
Gene symbols, descriptions,mean expression level ( SEM) per group, and one-way ANOVA p-values are reported. Genes presented are associated in the gene ontology categorywith calcium-related pathways and are altered significantly
with aging and countered by FKBP1b treatment.
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It seems of considerable interest that cytoskeletal remodeling
in dendritic spines has been shown to play a critical role in LTP
(Lynch and Baudry, 1987; Lynch et al., 2008; Briz and Baudry,
2016). In the present study, cytoskeletal gene downregulation
with aging and protection by FKBP1b was among the major ef-
fects and was confirmed at the protein level by IHC analyses of
MAP2, the primary MAP of somatodendritic compartments (Fig.
5). However, more than one FKBP1b-associated process likely par-
ticipates in memory formation. Accordingly, defining the precise
pathways linking FKBP1b overexpression to counteraction of age-
relatedmemory decline will require substantial further study.
The gene encoding calpain-1, a major Ca2-activated, cyto-
skeletal-degrading protease, was upregulated with aging and
downregulated by FKBP1b (Table 3). This is the inverse pattern
of that for cytoskeletal genes and suggests that calpain-1 upregu-
lation might mediate important aspects of downregulation and
degradation of the cytoskeleton during aging. Conversely, by
downregulating calpain-1 expression, FKBP1b overexpression
may restore or maintain neuronal structural integrity.
Efficacy and safety of ST and ST effects of FKBP1b
overexpression
Another goal of the present study was to test whether LT FKBP1b
overexpression in middle-aged animals could prevent the emer-
gence of cognitive impairment as effectively as ST FKBP1b can
reverse it (Gant et al., 2015). Results showed clearly that FKBP1b
overexpression did not lose behavioral efficacy over extended
timebecauseboth theLTandSTFKBP1b treatmentgroups substan-
tially outperformed ACs and performed similarly to each other and
to young animals (Fig. 2). These results show that cognitive impair-
ment can be prevented by LT treatment beginning in middle-aged
animals and reversed by ST treatment in aged animals.
An interesting question not addressed here is whether animals
already performing at a high baseline, including young animals
and the small percentage of aged animals that are unimpaired
(Ba¨ckman et al., 1996; Gallagher and Rapp, 1997; Tombaugh et
al., 2002; Rowe et al., 2003, 2007; Curlik et al., 2014;Me´nard et al.,
2015), show improved memory with FKBP1b. It will be impor-
tant in future studies to determine whether unimpaired animals
are resistant or sensitive to the actions of FKBP1b on memory.
Relative to safety issues, FKBP1b expression was significantly
higher in LT compared with ST rats (Fig. 3), indicating increased
expression over the 9-month exposure or that expression is greater
when initiated in middle-aged versus aged animals. Regardless, the
health of LT rats appeared comparable to that of ST or age-matched
vector control ratsbecause therewasonlyonedeathandnoapparent
morbidity among LT rats over the 9-month course of the experi-
ment. The clinical literature also indicates that AAV-mediated gene
overexpression is generally long lasting and safe in brain tissue, with
an extremely low probability of inducing oncogenic or other delete-
rious changes in DNA (Kaplitt et al., 2007; McCown, 2010).
Do normal-aging-induced cytoskeletal conditions model
preneurofibrillary tangle pathology of AD?
Advanced age is the leading risk factor for AD (Reitz et al., 2011),
suggesting that some processes that drive normal brain aging also
increase susceptibility to AD. Considerable evidence indicates
that Ca2 dysregulation is present in both normal brain aging
and AD (see Introduction) and therefore is positioned to play a
role in age-dependent susceptibility to AD. Cytoskeletal dysfunc-
tion, in the form of neurofibrillary tangles is one of the hallmarks
of AD pathology. It is correlated with synaptic degeneration and
characterized by microtubule rarefaction and hyperphosphoryla-
tion of theMAP tau (Wis´niewski andTerry, 1973;Grundke-Iqbal et
al., 1979; Masliah et al., 1991; Jicha et al., 1997; Serrano-Pozo et al.,
2011; Webster et al., 2014). Here, we found that hippocampal cy-
toskeletal gene expression is downregulated with aging and, in
parallel with cognitive function, is restored by FKBP1b, very
possibly viaCa2 signaling pathways. Accordingly, although tangles
arenot generallypresent in animalmodels ofnormalbrain aging,we
suggest that declining FKBP1b function and resulting Ca2 dys-
regulation during normal aging in animals recapitulate brain-
aging processes in humans that subtly degrade the cytoskeleton
and, in susceptible individuals, eventually result in irreversible
neurofibrillary tangles and AD.
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